NovelMed Therapeutics announced preliminary study results for its lead compound in two models of age-related macular degeneration (AMD).
Cleveland-NovelMed Therapeutics announced preliminary study results for its lead compound in two models of age-related macular degeneration (AMD).
Two independent preclinical investigations demonstrated that the company’s lead compound-an alternative pathway inhibitor-prevents the onset and progression of wet AMD. A reduction in neovascularization greater that 65% was also noted with a low dose.
Given the antibody’s mechanism of action, the drug could also control dry AMD. As a result, vision loss and associated inflammation could be controlled not only in AMD, but also in inflammatory-mediated orphan and non-orphan ocular diseases.
"Millions of antibodies can be developed, but the challenge lies in orchestrated testing to distill high potential clinical candidates,” said Rekha Bansal, PhD, founder and chief executive officer of NovelMed. “We have successfully developed a unique portfolio of high potential antibodies and believe that our drug candidates could revolutionize the treatment options for vision loss that occurs in orphan and non-orphan indications.”
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.